Bacterial Protein Acts as Prion in Yeast and E. coli

Clostridium botulinum produces a transcription factor that can aggregate and self-propagate a prion-like form, leading to genome-wide changes in gene expression in E. coli, according to a study.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Computer-generated image of anaerobic, spore-forming, Clostridium bacteriaCDC, JAMES ARCHERResearchers at Harvard Medical School used software to run through roughly 60,000 bacterial genomes in search of proteins that, in yeast, would be predicted to behave as prions—that is, become misfolded in a way that passes on the errant structure to like proteins. In doing so, they identified a version of the global regulator Rho encoded in the genome of Clostridium botulinum, the causative agent of botulism. When they injected Cb­-Rho into E. coli to examine the protein’s function, they found that the protein misfolded in a prion-like manner, rendering it nonfunctional and allowing genes normally suppressed by Rho to be expressed.

The study, published last week (January 13) in Science, is the first to identify a prion-like protein in bacteria, suggesting that the emergence of prions predates the evolutionary split between eukaryotes and bacteria,” the authors, from Harvard Medical School, wrote.

Bacterial proteins capable of acting like prions could help the microbes to adapt to environmental changes. One of the genes liberated from Rho suppression, for example, allowed E. coli to better adapt to ethanol exposure. Because prions pass on their misfolded shape to like proteins, they may allow bacteria evolve without genomic changes. “Bacteria might need quick responses to their environment, such as dealing with antibiotics,” Peter Chien, a bacterial biochemist at the University of Massachusetts Amherst, who was not involved in the research, told ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies